2024-10-07 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**Company Overview:** Merck & Co Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

1. **Relative Performance:**
   - MRK has a cumulative return of 70.55%, trailing the S&P 500 (VOO) by 62.59%. This places its relative performance at the 22.13th percentile of its historical range, indicating a period of underperformance.

2. **Recent Price Movement:**
   - Closing price: 109.77
   - 5-day moving average: 112.07
   - 20-day moving average: 114.91
   - 60-day moving average: 117.24
   - MRK's price is currently trading below its short-term moving averages, suggesting potential downward pressure in the near term. 

3. **Technical Indicators:**
   - **RSI (18.86):** The RSI is deep in oversold territory, potentially indicating an oversold condition and potential for a bounce.
   - **PPO (-0.51):** The PPO is negative and declining, suggesting a weakening momentum. 
   - **Delta_Previous_Relative_Divergence (-23.39):** This indicates a short-term bearish trend. 
   - **Expected_Return (0.0%):**  The expected return is 0.0% over the next 5 years, reflecting a potential underperformance relative to the S&P 500.

4. **Recent Earnings & Outlook:**
   | Date | EPS | Revenue |
   |---|---|---|
   | 2024-08-05 | 2.15 | 16.11 B$ |
   | 2024-05-03 | 1.88 | 15.78 B$ |
   | 2023-11-03 | 1.87 | 15.96 B$ |
   | 2023-08-07 | -2.35 | 15.04 B$ |
   | 2024-08-05 | -2.35 | 15.04 B$ |

   - The most recent earnings report (2024-08-05) showed an EPS of 2.15, beating analyst expectations by a small margin.  However, the company faces challenges from generic competition for key products. 

5. **News & Recent Issues:**
   - **Market Outlook:**  MRK is facing generic competition for several of its blockbuster drugs, which is putting pressure on its revenue growth. However, the company is investing in its pipeline of new drugs and vaccines, which could drive future growth. 
   - **Analyst Opinions:** Analysts have mixed opinions on MRK, with some expressing concerns about generic competition while others are optimistic about its future prospects.
   - **Performance Highlights:** MRK has a history of strong dividend payments and has consistently outperformed the market over the long term. 

**Overall Analysis:**
MRK is currently facing headwinds from generic competition, which is impacting its short-term performance. While the company has a strong history of dividend payments and is investing in its pipeline of new drugs, its expected return is currently below the S&P 500. The recent price action and technical indicators suggest potential downward pressure in the near term. Investors should monitor the company's progress on its new drug development and its ability to navigate generic competition. 
